No connection

Search Results

ADMA vs INDV

ADMA
ADMA Biologics, Inc.
BEARISH
Price
$15.15
Market Cap
$3.61B
Sector
Healthcare
AI Confidence
85%
INDV
Indivior Pharmaceuticals, Inc.
NEUTRAL
Price
$30.54
Market Cap
$3.82B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ADMA
25.25
INDV
18.62
Forward P/E
ADMA
10.98
INDV
8.87
P/B Ratio
ADMA
7.55
INDV
-38.95
P/S Ratio
ADMA
7.07
INDV
3.08
EV/EBITDA
ADMA
18.04
INDV
10.01

Profitability

Gross Margin
ADMA
57.38%
INDV
84.02%
Operating Margin
ADMA
45.09%
INDV
37.15%
Profit Margin
ADMA
28.8%
INDV
16.95%
ROE
ADMA
35.56%
INDV
--
ROA
ADMA
21.5%
INDV
19.22%

Growth

Revenue Growth
ADMA
18.4%
INDV
19.7%
Earnings Growth
ADMA
-52.8%
INDV
376.2%

Financial Health

Debt/Equity
ADMA
0.17
INDV
--
Current Ratio
ADMA
6.71
INDV
0.71
Quick Ratio
ADMA
3.54
INDV
0.49

Dividends

Dividend Yield
ADMA
--
INDV
--
Payout Ratio
ADMA
0.0%
INDV
0.0%

AI Verdict

ADMA BEARISH

ADMA's Piotroski F-Score of 3/9 indicates weak financial health, signaling distress risk despite strong profitability metrics. The company trades at a high P/E of 25.25 and Price/Sales of 7.07, significantly above sector averages, suggesting overvaluation. While gross and operating margins are impressive (57.38% and 45.09%), earnings have collapsed YoY by 52.8%, undermining growth credibility. Insider selling totaling $1.58M in the last six months, including multiple large sales by the CEO, reinforces bearish sentiment. The Graham Number of $5.21 and intrinsic value of $4.2 suggest deep undervaluation, but the current price of $15.15 reflects a premium driven by speculative growth expectations rather than fundamentals.

Strengths
Exceptional gross and operating margins (57.38% and 45.09%) indicate strong pricing power and cost control
High ROE of 35.56% demonstrates efficient use of equity capital
Low debt/equity ratio of 0.17 and high current ratio of 6.71 signal strong financial stability
Risks
Piotroski F-Score of 3/9 indicates weak financial health and high distress risk
Earnings have declined sharply by 52.8% YoY, contradicting revenue growth of 18.4%
Insider selling of $1.58M in six months, including multiple large sales by the CEO, signals lack of confidence
INDV NEUTRAL

INDV presents a stark contrast between operational excellence and financial fragility, highlighted by a weak Piotroski F-Score of 2/9. While the company exhibits explosive earnings growth (376% YoY) and trades significantly below its intrinsic value of $48.38, its balance sheet is highly distressed with a negative Price/Book ratio of -38.95 and a Current Ratio of 0.71. The forward P/E of 8.87 suggests an attractive valuation for growth, but the underlying solvency risks prevent a bullish rating. The investment thesis relies entirely on continued high-margin growth to offset structural financial weaknesses.

Strengths
Exceptional gross margins (84.02%) and operating margins (37.15%)
Explosive YoY earnings growth of 376.20%
Strong earnings track record with 3/4 recent quarters beating estimates
Risks
Severe financial health warning indicated by Piotroski F-Score of 2/9
Negative shareholders' equity as evidenced by Price/Book of -38.95
Liquidity risk with a Current Ratio (0.71) and Quick Ratio (0.49) well below 1.0

Compare Another Pair

ADMA vs INDV: Head-to-Head Comparison

This page compares ADMA Biologics, Inc. (ADMA) and Indivior Pharmaceuticals, Inc. (INDV) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile